Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 129 of 144 pages ‹ First < 127 128 129 130 131 > Last ›
HSL7607
Tsai AC.
Policies to regulate gifts to physicians from industry
JAMA 2003; 290:(13):1776
HSL7608
Tatchell M.
Free trade and the PBS
Pharmacy Review 2003; 27:(3):21-22
HSL7609
Trading in our health system?
Pharmacy Review 2003; 27:(3):19-21
HSL7610
Strict controls on advertising
Pharmacy Review 2003; 27:(3):14, 19
HSL7611
Free rein for drug ads?
Consumer Reports 2003; 68:(2):33-37
HSL7612
Koopmanschap MA, Rutten FF.
The drug budget silo mentality: The Dutch case
Value in Health 2003; 6:(4):46-51
HSL7613
Hurley D.
Federal guidance
Pharmacy Practice News 2003; 30:(7):
HSL7614
McCue MT.
The rock meets the hard place on drug prices and research
Managed Healthcare Executive 2003; 13:(8):1
HSL7615
Franquesa N.
APS: additional value in the pharmacy?
Farmaceutico El 2003; (295):66,68,70,72,
HSL7616
Johanson V.
The Pan aftermath - where to from here?
Australian Journal of Pharmacy 2003; 84:(1001):666-7
HSL7617
Moffitt CM, MacLean EA, Noris-sullivan V.
Helping seniors understand the healthcare system: A pharmacist directed educational series
ASHP Midyear Clinical Meeting 2003;
HSL7618
Drug advertising helps patients
Michigan Pharmacist 2003; 41:(4):39
HSL7619
Tsang JP.
Hospital to home
Pharmaceutical Executive 2003; 23:(7):84,86,88,90,92
HSL7620
Ho J.
Extending the product lifeline
Pharmaceutical Executive 2003; 23:(7):70,72,74,76
HSL7621
Schreiber C.
The pivotal prescribers
Pharmaceutical Executive 2003; 23:(7):62,64,66,68
HSL7622
Keeling P, Meade P.
How to make Rx-Dx alliances
Pharmaceutical Executive 2003; 23:(7):48,50,52,54,56,58,60
HSL7623
Wechsler J.
The push for generics challenges manufacturers
Pharmaceutical Technology 2003; 27:(7):26,28,30,32,34
HSL7624
Gaughan D.
Deficiencies observed during inspection
Irish Pharmacy Journal 2003; 81:(5):208-210
HSL7626
Direct-to-consumer drug advertising: survey results
WHO Drug Information 2003; 17:(1):15
HSL7630
Tatchell M.
Controlling drug expenditure in Europe
Pharmacy Review 2003; 27:(1):28-9
HSL7631
Murawski MM, Mychaskiw MA, Surdej J.
Exploration of the relationship between health-related quality of life and the price of pharmaceutical products
Drug Information Journal 2003; 37:(2):221-231
HSL7632
Vos LO.
Bring in the reinforcements
Pharmaceutical Executive 2003; 23:(5):82-83
HSL7633
A forlorn end to the PIIP scheme?
Australian Journal of Pharmacy 2003; 84:(998):348
HSL7634
Pal S.
More time needed for drug approvals
US Pharmacist 2003; 28:(5):12, 15
HSL7635
Tarnoff S, Kowalski G, Bauer B.
Neglected prescribers
Pharmaceutical Executive 2003; 23:(5):24,26,28
HSL7636
Perper E.
3-D marketing
Pharmaceutical Executive 2003; 23:(5):138,140,142,144
HSL7637
Frank RG.
Perspective - Government commitment and regulation of prescription drugs
Health Affairs 2003; 22:(3):46-48
HSL7638
DTC ad battle heals up
Pharmaceutical Executive 2003; 23:(5):22
HSL7639
Miller J.
Bar code requirement would lead to adoption of efficient technology
Managed Healthcare Executive 2003; 13:(5):42, 43, 45
HSL7642
Kalb PE, Dunlop KO, McEnroe DC, Stein SD.
Direct-to-consumer marketing: the Food and Drug Administration is not alone.
Food Drug Law J 2003; 58:(1):25-33
HSL7643
Rao DA, Srinivas S.
OTC status for prescription drugs
Pharma Times 2003; 35:(2):17-18
HSL7645
Waltz JA.
CMS report analyzes factors affecting the marketing of prescription drugs
Drug Benefit Trends 2003; 15:(3):23-24,27
HSL7646
Fridman GA, Zimerman CA, Bregni C.
Consumption of antidepressant and anxiolytic drugs in Argentina in 1998
Ars Pharmaceutica 2003; 43:(1-3):5-12
HSL7647
Barlas S.
Some drug ads don't "ad" up
P and T 2003; 28:(1):19
HSL7648
Novelli WD.
Shake hands on Rx drugs for Medicare
Pharmaceutical Executive 2003; 23:(2):18, 20
HSL7649
New obstacles slow efforts to speed generics to market
Drug Benefit Trends 2003; 15:(2):16-17
HSL7651
Trimble LT, Ashby DM, Geize SB, Thomasset KB.
Cost-benefit analysis of indigent care programs for inpatients in a large academic medical center
ASHP Summer Meeting 2003; 60:
HSL7653
Report criticizes FDA's oversight of DTC ads
American Journal of Health System Pharmacy 2003; 60:(2):122,126
HSL7841
Millenson M
Getting Doctors to Say Yes to Drugs: The Cost and Quality Impact of Drug Company Marketing to Physicians
: Blue Cross and Blue Shield Association 2003
http://web.archive.org/web/20071026063406/http://www.bcbs.com/betterknowledge/cost/Drug_Co_Marketing_Report.pdf
HSL7865
Flynn FJ.
What have you done for me lately? Temporal adjustments to favor evaluations.
Organizational Behavior and Human Decision Processes 2003; 91:(1):38-50
http://www.francisflynn.com/papers/WhatHaveYouDoneForMeLately.pdf
HSL19378
Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG; International Stroke Trial Collaborative Group; European Carotid Surgery Trial Collaborative Group.
Evaluating non-randomised intervention studies.
Health Technol Assess 2003; 7:(27):iii-x,
http://www.hta.ac.uk/execsumm/summ727.htm
HSL9703
Wechsler J.
Drug pricing concerns shape policy decisions
Pharmaceutical Technology Europe 2003; 15:(12):22-24
HSL9704
Albedo A.
One step further in EU medicine lobster quadrille
Pharmaceutical Technology Europe 2003; 15:(11):12-17
HSL9738
Backman J.
Use of antidepressants in deliberate self-poisoning - Psychiatric diagnoses and drugs used between 1987 and 1997 in Lund, Sweden
Social Psychiatry and Psychiatric Epidemiology 2003; 38:(12):684-689
http://link.springer-ny.com
HSL9779
Madsen S, Huse J, Roksvaag PO.
Pharmacy customers' attitude to generics
Tidsskrift for den Norske Laegeforening 2003; 123:(6):792-793
HSL9789
Akram G, Roberts K.
Pharmacists' management of over-the-counter medication requests from methadone patients
Journal of Substance Use 2003; 8:(4):215 - 222
HSL9793
Ekedahl A.
Unused Drugs Returned to Pharmacies - A Few Patients Return a Large Proportion of the Unused Drugs
Journal of Social and Administrative Pharmacy 2003; 20:(6):257-258
HSL9795
Overo J.
OTC antifungal drugs [2] (multiple letters)
Ugeskrift for Laeger 2003; 165:(9):933-934
HSL9879
Husain N.
Challenges for pharmacists in India
Pharmaceutical Journal 2003; 271:(7280):885-886
HSL9880
Mason P.
Pharmacy in Australia
Pharmaceutical Journal 2003; 271:(7280):883-884
HSL9881
Ludzker DH.
Let us not follow the United States [4]
Pharmaceutical Journal 2003; 271:(2779):812
HSL9882
Two developments widen availability of oseltamivir for 'flu
Pharmaceutical Journal 2003; 271:(7279):805
HSL9886
Work in progress
Veterinary Record 2003; 153:(25):761-762
HSL9888
Ganestam F, Lundborg CS, Grabowska K, Cars O, Linde A.
Weekly antibiotic prescribing and influenza activity in Sweden: a study throughout five influenza seasons.
Scand J Infect Dis 2003; 35:(11-12):836-42
HSL9892
Rhodes J.
Components of the Pharmaceutical Industry Are Converging
BioPharm International 2003; 16:(12):106
HSL9893
Wechsler J.
Risk Management and Pricing Concerns Shaped FDA Policy in 2003
BioPharm International 2003; 16:(12):16-17
HSL9894
Wilson KA, Jesson J .
Dispensing activity in a community pharmacy-based repeat dispensing pilot project
International Journal of Pharmacy Practice 2003; 11:(4):225-232
HSL9897
Thalidomide
Australian Prescriber 2003; 26:(6):150-151
HSL9898
Glokler C, Graefe T.
Advertising OTC drugs at reduced prices
Deutsche Apotheker Zeitung 2003; 143:(48):73-77
HSL9899
Muller-bohn T.
The combination model and its implications: Business administration for the pharmacy 2004: Part 3
Deutsche Apotheker Zeitung 2003; 143:(48):65-69
HSL9900
Herzog R.
Acting in crisis. Part 4: Future price fixing in the OTC segment - A question of survival!
Deutsche Apotheker Zeitung 2003; 143:(48):56-64
HSL9903
Schmidt E, Wong R.
'New' FDA delivers in 2003
Nature Reviews Drug Discovery 2003; 2:(12):941-942
HSL9904
Reprimand for pharmacist who endorsed erroneous scripts for £3,700 overpayment
Pharmaceutical Journal 2003; 271:(7277):757
HSL9905
A new standard coding system for reporting patient safety incidents
Pharmaceutical Journal 2003; 271:(7277):749
HSL9914
Voelker R.
Northern Rxposure: US, Canada Clash on Cross-Border Medication Sales
Journal of the American Medical Association 2003; 290:(22):2921-2925
HSL9915
Muller-Bohn T
How much is the OTC trade worth? Part 4
Deutsche Apotheker Zeitung 2003; 143:(49):65-69
HSL9916
May U.
Effects of the German public health system modernization act on the over-the counter medicines market
Pharmazeutische Industrie 2003; 65:(11):1085-1092
HSL9917
Goldenberg MM.
Drug Safety Revisions: FDA Update
P and T 2003; 28:(8):
HSL9918
Nash DB.
The AMCP's Drug Dossier Format
P and T 2003; 28:(10):624
HSL9919
Thawani V, Pande S, Turankar A.
Nicotine replacement drug being sold on pavement shops
Indian Journal of Pharmacology 2003; 35:(6):402, 403
http://www.doaj.org/openurl?genre=article&issn=0253-7613&volume=35&issue=6&spage=402
HSL9920
Adcock H.
Statin set to become next big POM-to-P switch: Is this good news for patients?
Pharmaceutical Journal 2003; 271:(7276):705
HSL9921
Scopoderm reclassification
Pharmaceutical Journal 2003; 271:(7276):704
HSL9922
Statins form part of the PAGB's draft OTC advertising guidance
Pharmaceutical Journal 2003; 271:(7276):699
HSL9923
Simvastatin could become a pharmacy medicine within the next six months
Pharmaceutical Journal 2003; 271:(7276):699
HSL9924
Telmisartan + hydrochlorothiazide
Prescrire International 2003; 12:(68):219
HSL9925
Appearances can be deceptive
Prescrire International 2003; 12:(68):202
HSL9926
Szelag A, Merwid-lad A, Trocha M, Skrzypiec M, Smereka A.
Pathomechanisms of drug hepatotoxicity
Gastroenterologia Polska 2003; 10:(5):425-9
HSL9929
Perkins ML.
Talk to local GPs [9]
Pharmaceutical Journal 2003; 271:(7274):645
HSL9931
Glass HE.
Series of regulatory rulings guide FDA decision making
Drug Benefit Trends 2003; 15:8-11
HSL9936
Decaudin B, Vion D.
To carry out a drug prescription "outside of authorized marketing demand" in hospital pharmacy. Example is prescription of oxybate sodium
Biofutur 2003; (238):44-46
HSL9941
Massive illegal supplies of co-proxamol lead to striking-off and reprimand
Pharmaceutical Journal 2003; 271:(7273):629-630
HSL9942
Postcode prescribing review
Pharmaceutical Journal 2003; 271:(7273):604
HSL9946
McLeod RL, Tulshian DB, Hey JA.
Novel pharmacological targets and progression of new antitussive drugs
Expert Opinion on Therapeutic Patents 2003; 13:(10):1501-1512
HSL9948
GSK's Paxil given notice
Nature Reviews Drug Discovery 2003; 2:(5):342
HSL9955
Potter JE, Moore AM, Byrd TL.
Cross-border procurement of contraception: estimates from a postpartum survey in El Paso, Texas
CONTRACEPTION 2003; 68:(4):281-7
http://linkinghub.elsevier.com/retrieve/pii/S001078240300177X
HSL9956
Bellingham C.
How self-care is being made a reality
Pharmaceutical Journal 2003; 271:(7270):486
HSL9957
OTC omeprazole approved for heartburn
WHO Drug Information 2003; 17:(3):170
HSL10234
Nimesulide temporarily suspended
WHO Drug Information 2003; 17:(3):169
HSL10235
Lyndon B.
Should psychiatrists lie to access suitable treatment for their patients?
Australasian Psychiatry 2003; 11:(3):347-349
http://www.blackwell-synergy.com/rd.asp?code=APY&vol=11&page=347&goto=abstract
HSL10236
Jose VM.
Recent trends in the utilization of 'NSAIDs' in a tertiary care hospital
Indian Journal of Pharmacology 2003; 35:(5):318-319
http://www.doaj.org/openurl?genre=article&issn=0253-7613&volume=35&issue=5&spage=318
HSL10238
How to help pharmacists and the industry be allies in concordance
Pharmaceutical Journal 2003; 271:(7269):467-468
HSL10239
Faking it
Pharmaceutical Journal 2003; 271:(2769):436
HSL10240
Hutton N.
Does mass marketing have a future?
Pharmaceutical Journal 2003; 271:(7268):424
HSL10242
Morgan SG, Mintzes B, Barer M.
The economics of direct-to-consumer advertising of prescription-only drugs: Prescribed to improve consumer welfare?
Journal of Health Services Research and Policy 2003; 8:(4):237-244
HSL10243
Allen LaPointe NM, Pamer CA, Kramer JM.
New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance
Pharmacotherapy 2003; 23:(10):1316-1321
HSL10246
'Unsatisfactory' for over-the-counter St. John's wort preparations
Deutsche Apotheker Zeitung 2003; 143:(40):51
HSL10250
Wechsler J.
Counterfeiting, compliance and controls
Pharmaceutical Technology Europe 2003; 15:(9):
HSL10251
Cannabis-based medicines - GW Pharmaceuticals. High CBD, high THC, medicinal cannabis - GW Pharmaceuticals, THC:CBD
Drugs in R and D 2003; 4:(5):306-309
HSL10253
Laplanche A.
Heparin prevention during hospitalisation in medical wards?
Prescrire International 2003; 12:(67):198-199
HSL10254
Generic version of OTC loratadine comes to market
Formulary 2003; 38:(9):518
Page 129 of 144 pages ‹ First < 127 128 129 130 131 > Last ›
